Acromegaly - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Acromegaly - Pipeline Review, H2 2016

Acromegaly - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Acromegaly - Pipeline Review, H2 2016
Published Sep 21, 2016
91 pages — Published Sep 21, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Acromegaly - Pipeline Review, H2 2016, provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
- The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing stra

  
Source:
Document ID
GMDHC8480IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Acromegaly Overview81
Therapeutics Development92
  Pipeline Products for Acromegaly Overview91
  Pipeline Products for Acromegaly Comparative Analysis101
Acromegaly Therapeutics under Development by Companies111
Acromegaly Therapeutics under Investigation by Universities/Institutes121
Acromegaly Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Acromegaly Products under Development by Companies161
Acromegaly Products under Investigation by Universities/Institutes171
Acromegaly Companies Involved in Therapeutics Development1816
  Aegis Therapeutics, LLC181
  Amryt Pharma plc191
  Antisense Therapeutics Limited201
  Chiasma, Inc.211
  Crinetics Pharmaceuticals, Inc.221
  DexTech Medical AB231
  Foresee Pharmaceuticals, LLC241
  Glide Pharmaceutical Technologies Limited251
  Ionis Pharmaceuticals, Inc.261
  Ipsen S.A.271
  Italfarmaco S.p.A.281
  Midatech Pharma Plc291
  Novartis AG301
  Peptron, Inc.311
  Strongbridge Biopharma plc321
  Sun Pharma Advanced Research Company Ltd.331
Acromegaly Therapeutics Assessment349
  Assessment by Monotherapy Products341
  Assessment by Target352
  Assessment by Mechanism of Action372
  Assessment by Route of Administration392
  Assessment by Molecule Type412
Drug Profiles4334
  AP-102 Drug Profile431
  atesidorsen sodium Drug Profile448
  COR-005 Drug Profile523
  FP-002 Drug Profile551
  IONIS-GHRLRx Drug Profile561
  ITF-2984 Drug Profile571
  L-779976 Drug Profile581
  octreotide acetate Drug Profile592
  octreotide acetate Drug Profile614
  octreotide acetate Drug Profile651
  octreotide acetate long acting Drug Profile662
  octreotide acetate SR Drug Profile681
  octreotide acetate SR Drug Profile691
  octreotide SR Drug Profile701
  pasireotide ER Drug Profile713
  Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors Drug Profile741
  Somadex Drug Profile751
  SXN-101959 Drug Profile761
Acromegaly Dormant Projects771
Acromegaly Discontinued Products781
Acromegaly Product Development Milestones7911
  Featured News &Press Releases791
    Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study791
    Jul 13, 2016: ATL1103 Patent Update801
    Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study811
    Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa821
    Jun 01, 2016: Antisense provides update on ATL1103 clinical trials821
    May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology831
    May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI841
    May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly841
    Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide851
    Apr 18, 2016: Chiasma Provides Update Regarding FDA s Complete Response Letter for Mycapssa New Drug Application851
    Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application861
    Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly861
    Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference871
    Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced881
    Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly882
Appendix902
  Methodology901
  Coverage901
  Secondary Research901
  Primary Research901
  Expert Panel Validation901
  Contact Us901
  Disclaimer911

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Acromegaly - Pipeline Review, H2 2016" Sep 21, 2016. Alacra Store. May 10, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acromegaly-Pipeline-Review-H2-2016-2088-16577>
  
APA:
Global Markets Direct - Market Research. (2016). Acromegaly - Pipeline Review, H2 2016 Sep 21, 2016. New York, NY: Alacra Store. Retrieved May 10, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acromegaly-Pipeline-Review-H2-2016-2088-16577>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.